Perrigo launches generic Zaditor
This article was originally published in The Tan Sheet
Executive SummaryPerrigo ships its generic of Novartis Pharmaceuticals' Zaditor, a ketotifen fumarate ophthalmic solution, .025 percent, the Allegan, Mich.-based private labeler says in a March 15 release. Perrigo CEO Joseph Papa said the firm is "excited to launch into a new adjacent OTC category, ophthalmics." Zaditor is a solution used to temporarily prevent allergic conjunctivitis. Wolters Kluwer data estimates the annual sales of Zaditor in the last 12 months reached $15 million, Perrigo said. Competition in the eye-care market increased with the recent launch of Johnson & Johnson/McNeil's Zyrtec Allergy Eye Relief Drops and Schering-Plough's Claritin Eye, which also contain ketotifen fumarate as the active ingredient (1"The Tan Sheet" Jan. 11, 2010)
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.